Vertex Pharmaceuticals Announces Results From Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-ranging Study Evaluating Safety And Efficacy Of Vx-993 In Treating Acute Pain After Bunionectomy Surgery

Benzinga · 08/04 20:05

– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –

– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm –